Bioceres Crop Solutions Reports Fiscal Third Quarter 2025 Financial and Operational Results

Total revenues in 3Q25 were $60.6 million

3Q25 net loss was $1.6 million and Adjusted EBITDA¹ was $9.0 million

Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted.

Financial & Business Highlights

• Total revenues were $60.6 million in 3Q25, compared to $84.0 million for the same quarter last year, primarily due to an expected $15.7 year-over-year negative difference related to the accrual in 3Q24 of Syngenta’s initial downpayment.
• Net cash flow generated by operating activities reached $23.3 million during 3Q25, an improvement of $40.7 million compared to 3Q24, driven by efficiencies in working capital management.
• Operating profit was $0.9 million and net loss was $1.6 million. Adjusted EBITDA¹ for the quarter was $9.0 million.
• Obtained EPA registration of Rinotec™ insecticide and nematicide platform, a game changing biological solution for integrated pest management.

Management Review

Mr. Federico Trucco, Bioceres´ Chief Executive Officer, commented: “Our third fiscal quarter is typically uneventful, as it falls in the off-season for most of our geographies. This year, however, it stands out for a non-P&L achievement: our exceptional cash flow performance. The $40 million improvement on a year-over-year basis reflects disciplined execution across the organization, and we are very pleased with the outcome.

An important contributor to our cash flow performance this quarter is the shift in our seed business strategy, which is also enabling a more focused approach. As we transition organizationally, we have exchanged some non-core traits and IP, streamlining third party royalty commitments and other obligations, and positioning us to better serve our partners and licensees. We also, implemented a significant reduction in operating expenses — mainly in seed production and commercialization — by transferring these activities to key customers. Some early benefits of these changes are already visible this quarter, with more expected in the quarters to come.”

We are also very excited about the EPA approval of Rinotec in the US. We can now offer growers and partners a full suite of on-seed and on-field biological solutions — biocontrols and plant health alike — for both cash and row crops across the world’s largest agricultural markets. We have never been better positioned to put sustainable innovation with an agronomic edge in the hands of growers.”

Mr. Milen Marinov, Bioceres´ Chief Commercial Officer, added: "Rinotec technology is a novel platform for insect, nematode and mite control in row and specialty crops. With regulatory approvals now secured in both the US and Brazil, Rinotec will expand our presence in seed treatment, foliar and soil applied markets. This innovation underscores our commitment to scalable, bio-based solutions that deliver strong agronomic performance with a lower environmental footprint. It exemplifies how innovation in biologicals can drive growth beyond the limits of traditional chemistry.”

Mr. Enrique Lopez Lecube, Bioceres´ Chief Financial Officer, noted: "We made strong progress in optimizing cash flow and realigning our cost structure to market conditions, despite this being a seasonally low quarter. After a challenging first half, it was crucial to drive progress in managing working capital and our efforts to tighten inventory management and accounts receivables yielded tangible results this quarter. Enhancing cash generation and ensuring efficient capital allocation— with working capital as a key component—is central to our strategy as we prepare to fully leverage our portfolio of biological solutions in normalized market conditions and as new product introductions gain traction.”

Key Financial Metrics

3Q25 Summary: Third quarter revenue, gross profit and gross margin results reflect expected year-over-year declines, primarily related to the absence of the Syngenta downpayment accrual that had positively impacted both metrics in 3Q24. Usual third-quarter seasonal slowdown and reduced market activity in Argentina was reflected in sales performance, particularly in Crop Nutrition and Crop Protection.

The Company continues to take action to improve its cash flow performance and align its overall cost structure and balance sheet with current market conditions. After tightening inventory management in the first half of the FY, during the third quarter the Company focused on improving its accounts receivables performance — delivering strong operating cash flow. Net cash flow from operating activities reached $23.3 million during 3Q25, a $40.7 million increase compared to the year-ago quarter, primarily driven by inventory and accounts receivables management. The primary use of cash generated by operations was to reduce financial debt and bolster the cash position.

Adjusted EBITDA¹ decreased in line with gross profit. The anticipated decrease in Crop Nutrition results was partially offset by a $7.5 million contribution on Other Income from actions taken under the new seed reorganization strategy. This contribution results from a beneficial exchange of intangible seed assets, as some non-core traits from the Company’s soybean tilling library have been exchanged in lieu of third-party royalty obligations and expanded geographical rights to continuing traits in the portfolio.

During the quarter, Bioceres obtained EPA registration of Rinotec, a game changing insecticide and nematicide platform, that will offer growers a powerful alternative to reduce reliance on traditional pesticides for row and specialty crops alike. With both U.S. and Brazilian registrations now in place, the Company is poised to capitalize on growing market opportunities in two of the world’s largest agricultural economies. The technology comes with agronomic and economic benefits suitable for conventional agriculture.

For a full version of Bioceres’ third quarter fiscal year 2025 earnings release, click here.

Fiscal Third Quarter 2025 Earnings Conference Call

Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website.

To access the call, please use the following information:

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices.

The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. Through its HB4® program, the company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here.

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250521310824/en/